Abstract
Propafenone is a new class IC antiarrhythmic agent that has just been released in the United States for use in treatment of malignant ventricular arrhythmias (Rythmol, Knoll Pharmaceuticals, Whippany, New Jersey). It was first marketed in Europe in 1977, and has gained wide acceptance there and in Canada for the treatment of various types of ventricular and supraventricular arrhythmias. It acts primarily by inhibiting the fast inward sodium current. Like flecainide and encainide, it has very prominent conduction slowing effects, with relatively little change in repolarization and corrected QT interval.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
